Key Takeaways Shares of PFE fell after 2026 guidance projected $59.5B-$62.5B in revenue and adjusted EPS of $2.80-$2.90.PFE expects COVID product sales to decline in 2026 as patent losses rise over $3B in 2027 and$6B in 2028.PFE reaffirmed $7.2B in cost cuts by 2027, but said new launches won't drive a growth inflection until 2029.Shares of Pfizer (PFE) dropped more than 3% on Tuesday after the company announced its financial outlook for the full year 2026, which fell short of investor expectations. The co ...